GARDP

CARB-X published compulsory guidance on Monday to ensure that new antibacterial products brought to market by its funded companies are used responsibly and made available to people in LMICs.

The Stewardship and Access Plan Development Guide—created by the Boston University-led nonprofit and its partners, including the Access to Medicine Foundation, the Gates Foundation, the Global Antibiotic Research and Development Partnership, the Global Antimicrobial Resistance Innovation Fund, and…

The Geneva-based Global Antibiotic Research and Development Partnership (GARDP) announced last week that it has signed a memorandum of understanding with India’s Dr. Reddy’s and Aurigene Pharmaceutical Services to explore joint opportunities to make novel drug-resistant gonorrhea treatment zoliflodacin “accessible in low- and middle-income countries (LMICs), including South Africa, Thailand and India.”

The press release did not detail deal terms outside of GARDP’s responsibility to…

CARB-X announced two new investments on Tuesday. The first, worth up to $8.77 million, will go to Germany’s Helmholtz Centre for Infection Research (HZI) and the Dortmund-based Lead Discovery Center to develop a drug to prevent S. aureus-induced lung tissue damage in pneumonia patients. The second award—up to $6.31 million to a team of HZI-affiliated researchers—will fund the development of a new treatment for P. aeruginosa infections in cystic fibrosis patients.

In other news, the…

Mentions:

The Global Antibiotic Research and Development Partnership (GARDP) announced last week that it has signed a memorandum of understanding with India’s Bugworks Research for regulatory strategies and R&D for drug-resistant antibiotic treatments for high-burden countries.

In other news, the BEAM (Biotech companies in Europe combating Antimicrobial Resistance) Alliance, which includes approximately 70 small- and medium-sized European drug developers, urged the European Union and its…

The Global Antibiotic Research and Development Partnership (GARDP) announced two agreements to help develop antibiotics against three carbapenem-resistant (CR) pathogens that WHO has listed as critical.

First, GARDP and Venatorx Pharmaceuticals said last week that the nonprofit will provide development support for the Pennsylvania-based company’s investigational antibiotic against CR Enterobacterales and P. aeruginosa in return for exclusive rights to distribute the drug, cefepime-…

London-based think tank Chatham House issued its first evaluation of the British government’s 2016 Review on Antimicrobial Resistance last week, saying the AMR Review has had a “global impact as an advocacy tool,” but there has been “very little progress” on transforming R&D incentives for antibiotics, vaccines and diagnostics.

The report acknowledged that initiatives such as CARB-X, the Fleming Fund and the Global Antibiotic Research & Development Partnership have “…

The nonprofit Global Antibiotic Research and Development Partnership (GARDP) and Entasis Therapeutics announced this week that they are starting Phase 3 trials of the Massachusetts-based company’s new oral antibiotic for the treatment of uncomplicated gonorrhea.

GARDP is fully funding the trials, which plan to enroll 1,000 adults with urogenital gonorrhea across four countries, a joint press release said. The results (expected in 2021) will compare zoliflodacin against the current…

Britain’s National Health Service (NHS) announced this week that it will test a subscription model that will pay pharma companies up front for access to antibiotic drugs based on their usefulness to the NHS, rather than by the quantity of drugs sold. According to a government press release, the model will encourage companies to invest in R&D for new drugs to combat antimicrobial resistance (AMR).

In other AMR funding news, the Global Antibiotic Research & Development…

Mentions:

Japanese companies Eisai and Takeda announced this week that they are opening their chemical libraries to the Global Antibiotic Research & Development Partnership to screen for novel compounds with antibacterial activity.

Institut Pasteur Korea will carry out the testing against bacteria identified as a critical priority on WHO’s global priority pathogen list.